Subject: RCN
Management Change in Moberg Pharma
STOCKHOLM, April 19th, 2018 /PRNewswire/ --
Moberg Pharma AB (OMX: MOB) announces that Kjell Rensfeldt, VP Research and Development, will retire in the fall but remain with the company part-time as Senior Adviser.
On October 1st 2018, Kjell Rensfeldt, VP Research and Development, will retire from Moberg Pharma, but remain with the company in a part-time role as Senior Adviser. The process of finding his replacement has started.
"With extensive knowledge and experience, Kjell has contributed to the evolution of Moberg Pharma, especially through the development of Kerasal Nail® and MOB-015, where he has been instrumental. I've had the pleasure of working with Kjell since 2007 and I am highly grateful for his efforts over the years. I look forward to continuing our collaboration in his role as Senior Advisor to the company", says Peter Wolpert, CEO Moberg Pharma.
About this information
This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 9.30 a.m. CET on April 19th, 2018.
For additional information, please contact:
Peter Wolpert, CEO, telephone: +1 908 432 22 03 (US), +46 70 735 71 35, e-mail: [email protected]
Anna Ljung, CFO, telephone: +46 707 66 60 30, e-mail: [email protected]
This information was brought to you by Cision http://news.cision.com
http://news.cision.com/moberg-pharma/r/management-change-in-moberg-pharma,c2498924
The following files are available for download:
|
Management change in Moberg Pharma |
SOURCE Moberg Pharma
These press releases may also interest you
|
News published on and distributed by:
